IP Library Granted Patent US 10,576,055
Granted Patent B2
US 10,576,055 · App. 16/206,521 · Granted Mar 3, 2020

Pharmaceutical compositions of dimethyl fumarate

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,576,055
App. No.
16/206,521
Granted
Mar 3, 2020
Kind
B2
Abstract

Pharmaceutical compositions and dosage forms of dimethyl fumarate containing low levels of certain impurities are disclosed.

Claims (25)

1. A pharmaceutical composition, comprising:

(a) dimethyl fumarate in solid form; and

(b) one or more compounds of Formula (III):

isomers thereof and salts of any of the foregoing, wherein:

each of R 9 and R 10 is independently chosen from hydrogen and methyl.

2. The pharmaceutical composition of claim 1 , wherein the one or more compounds of Formula (III) are selected from: dimethyl oxirane-2,3-dicarboxylate; 3-(methoxycarbonyl)oxirane-2-carboxylic acid; oxirane-2,3-dicarboxylic acid; isomers thereof and salts of any of the foregoing.

3. The pharmaceutical composition of claim 1 , in the form of a powder.

4. The pharmaceutical composition of claim 1 , comprising a pharmaceutically acceptable vehicle.

5. The pharmaceutical composition of claim 4 , wherein the pharmaceutically acceptable vehicle is selected from the group consisting of a carrier, a diluent, an excipient, a wetting agent, an emulsifier, a buffer, a stabilizer, a thickener, a lubricant, a coloring agent and combinations thereof.

6. The pharmaceutical composition of claim 1 , wherein the composition is substantially free of PVP, PEG and polysorbate surfactant.

7. The pharmaceutical composition of claim 1 , comprising an antioxidant.

8. The pharmaceutical composition of claim 1 , comprising a free radical scavenger.

9. The pharmaceutical composition of claim 1 , wherein the one or more compounds of Formula (III) comprises dimethyl oxirane-2,3-dicarboxylate.

10. A dosage form for treating multiple sclerosis, comprising:

(a) a therapeutically effective amount of dimethyl fumarate in solid form;

(b) one or more compounds of Formula (III):

isomers thereof and salts of any of the foregoing, wherein:

each of R 9 and R 10 is independently chosen from hydrogen and methyl; and

(c) a pharmaceutically acceptable vehicle.

11. The dosage form of claim 10 , wherein the one or more compounds of Formula (III) are selected from dimethyl oxirane-2,3-dicarboxylate; 3-(methoxycarbonyl)oxirane-2-carboxylic acid; oxirane-2,3-dicarboxylic acid; isomers thereof and salts of any of the foregoing.

12. The dosage form of claim 10 , in the form of a tablet or capsule.

13. The dosage form of claim 10 , wherein the dosage form is substantially free of PVP, PEG and polysorbate surfactant.

14. The dosage form of claim 10 , comprising an antioxidant.

15. The dosage form of claim 10 , comprising a free radical scavenger.

16. The dosage form of claim 10 , wherein the one or more compounds of Formula (III) comprises dimethyl oxirane-2,3-dicarboxylate.

Assignments (5)
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Mar 17, 2025
From: ARBOR PHARMACEUTICALS, LLC; AZURITY PHARMACEUTICALS, INC.; AZURITY PHARMACEUTICALS IRELAND LIMITED; SILVERGATE PHARMACEUTICALS, INC.
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070531/0487 →
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: AZURITY PHARMACEUTICALS, INC.; SILVERGATE PHARMACEUTICALS, INC.; ARBOR PHARMACEUTICALS, LLC; SLAYBACK PHARMA LIMITED LIABILITY COMPANY
Reel/Frame 070521/0299 →
SECURITY INTEREST Recorded Sep 20, 2021
From: ARBOR PHARMACEUTICALS, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 057544/0803 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 25, 2019
From: KARABORNI, SAMI; CHEN, WEI; MANTHATI, SURESH KUMAR
To: XENOPORT, INC.
Reel/Frame 051103/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 25, 2019
From: XENOPORT, INC.
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 051104/0283 →